Kidney targeting peptide-modified biomimetic nanoplatforms for treatment of acute kidney injury
Journal of Controlled Release · 2023
DOI: 10.1016/j.jconrel.2023.04.042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2023. Verfasst von Zhiwei Huang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, China; Research Institute of Pharmaceutical Sci…. Hauptthemen laut MEDLINE: Biomimetics, Acute Kidney Injury. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: Medical Science and Technology Project of Zhejiang Province.
Abstract (Originalsprache)
The management of acute kidney injury (AKI) imposes a significant medical burden. Due to the lack of effective drug transport vehicles, the administration of therapeutic agents for AKI cannot obtain the desired therapeutic effects. Kidney-targeted nanoparticles for renal delivery of drugs have shown promising potential as an emerging strategy for AKI therapy. However, these exogenous nanoparticles are rapidly cleared in the body and fail to achieve the expected renal targeting efficiency. Herein, we prepared the kidney targeting peptide-modified renal tubular epithelial cell membrane to coat zeolite imidazolate framework-8 nanoparticles for FGF21 delivery (KMZ@FGF21) for AKI treatment. KMZ@FGF21 could be efficiently internalized by renal cells and exhibited antioxidative, antiapoptotic and anti-inflammatory effects. A septic AKI murine model was established to assess the in vivo performance of KMZ@FGF21. The results showed that injected KMZ@FGF21 specifically accumulated in the injured kidney and exerted good renoprotective effects. This study provides an innovative thread for precise drug delivery in the treatment of various renal diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, China; Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chonnam National University, Gwangju 61186…
- Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chonnam National University, Gwangju 61186, Republic of Korea. Electronic address: cchun1130@chonnam.ac.kr.
- Department of Emergency, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, China. Electronic address: lxzpharm@163.com.
Förderung
- Medical Science and Technology Project of Zhejiang Province
Zitieren
APA
Huang, Z., Chun, C., & Li, X. (2023). Kidney targeting peptide-modified biomimetic nanoplatforms for treatment of acute kidney injury. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2023.04.042
Vancouver
Huang Z, Chun C, Li X. Kidney targeting peptide-modified biomimetic nanoplatforms for treatment of acute kidney injury. Journal of Controlled Release. 2023. doi:10.1016/j.jconrel.2023.04.042
BibTeX
@article{Huang2023,
author = {Huang, Zhiwei and Chun, Changju and Li, Xinze},
title = {Kidney targeting peptide-modified biomimetic nanoplatforms for treatment of acute kidney injury},
journal = {Journal of Controlled Release},
year = {2023},
doi = {10.1016/j.jconrel.2023.04.042}
}
EUVIMED